About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, August 6th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

Building Turbines, Inc. (BLDW)

PennyStocks24, Center Stage Stocks, SmallCapVoice, InsideBulls, Penny Trackers, Whisper from Wall Street, Otcstockexchange, and Pennystocktweeters.com reported earlier on Building Turbines, Inc. (BLDW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTC Pink Current Information, Building Turbines, Inc.is a developer and manufacturer of distinctive wind turbines, which can undergo mounting on building rooftops.A development stage renewable energy corporation, their pioneering and patented design is suited for commercial applications. It creates reliable, cost-effective, clean and on-site renewable electricity. In addition, the Company is focusing on vertically integrating into other renewable energy solutions to complete a total Green Energy Solution for any urban environment. Building Turbines has their headquarters in Austin, Texas.

The Company’s horizontal-axis wind turbines (HAWT) straightforwardly mount onto commercial buildings with flat roofs. The uni-directional design rests on HVAC-style curbs. It is mounted along the roof’s edge next to the parapet wall. The turbine is mounted on a strong steel frame. It has a low profile, low maintenance needs, and creates almost no noise or vibration.

The turbine leverages what is called a ‘parapet vortex’. This type of vortex naturally occurs as wind accelerates up the side of a building and crests over the rooftop edge. The centering of the turbine’s axle rod is in this vortex. It captures maximum electrical power generation capability from the wind.

Building Turbines has established a new subsidiary, Green City Planet.Mr.John Graham, Building Turbines’ Chief Executive Officer, stated, "The formation of Green City Planet, and other planned divisions, are an excellent example of implementing our vision of vertically, and/or horizontally integrating all technologies and aspects of renewable energy into a one stop shop for a total Green Energy Solution, for any urban environment."

In July, Building Turbinesannounced that Green City Planet signed a contract with The FreshBrew Group of Houston, Texas.The FreshBrew Group consists of a specialty small-batch roasting and gourmet quality coffee company and a premier, technology-driven vending services company.

This contract is to perform a complete lighting retrofit of their 90,000 sq. ft. warehouse, manufacturing facility, executive offices and all other interior and exterior lighting with cost saving LED Lighting.

Building Turbines, Inc. (BLDW), closed Tuesday’s trading at $0.046, up 4.55%, on 1,197,153 volume with 95 trades. The average volume for the last 60 days is 139,214 and the stock's 52-week low/high is $0.0021/$0.063.

SUTIMCo International, Inc. (SUTI)

Wallstreetlivechat, OurHotStockPicks, Xtremepicks, Pumps and Dumps, and PSSMS Newsletter reported earlier on SUTIMCo International, Inc. (SUTI), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

SUTIMCo International, Inc. is a holding company that employs a distinctive and established platform to launch new technology enterprises based on world-class university research discoveries. The Company,by way of their wholly owned subsidiary SUTIMCo, Inc., provides experienced management to early stage companies. This lessens risk and assures the expertise in launching and growing a new company. SUTIMCo International has their corporate headquarters inSanta Ana, California.

A multi-project business development company, SUTIMCoprincipally engages in the development of operating companies, companies in the pre-funding stage, and projects in the development process.The Company can additionally utilize the encyclopedic, informal knowledge of the inventor, his experience and his research team.

SUTIMCo International has a portfolio of technology and innovation start-ups, in partnership with over two-dozen of the nation's best research universities. Each of these business entities is undergoing advancement by the SUTIMCo management team and methodology.

At the end of April 2013,SUTIMCo International announced their outlook and technology focus for 2013. Upon reviewing more than 2,000 major university technologies, the Company’s management made the decision to center their attention around four very promising technology sectors based on Quality of Life, Long Haul Trucking, Water, and Oil & Gas. The four technology sectors that have been organized into business units are Water, Oil and gas remediation and extraction, Trucking equipment & Bio-Lubricants, and Quality of life.

In May,SUTIMCo International announced the appointment of Mr. Steve Nieman as Chairman of the Advisory board for the Company's Truck Equipment and Lubricants Business Unit.  Mr. Nieman will be instrumental in developing and adding key members with specific expertise to the Truck and Lubricant Technologies Business Unit. He will do this while properly structuring presentations for key investment groups.Mr. Nieman has extensive experience in global and North American transportation and distribution.

SUTIMCo International's Trucking Equipment & Biodregradable Lubricants Business Unit consists of four proprietary technologies. These are all centered on environmental safety and the reduction of fuel costs for the trucking industry. The four technologies are: Liberty Lube, Spray Rite, Dragon Fire, and MoniTire.

SUTIMCo International, Inc. (SUTI), closed Tuesday’s trading session at $0.0004, up 33.33%, on 54,595,000 volume with 37 trades. The average volume for the last 60 days is 12,929,990 and the stock's 52-week low/high is $0.0001/$0.019.

Northstar Global Business Services, Inc. (MDIN)

Wallstreetlivechat reported recently on Northstar Global Business Services, Inc. (MDIN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 1996, Northstar Global Business Services, Inc.’s commitment is to producing the best alternative healthcare products.The majority of the Company’s products use a proprietary or patented formula, spray delivery system, or ingredients. The Company formerly went by the name Med Gen, Inc. They changed their name to Northstar Global Business Services, Inc. in August of 2010. Northstar’s shares trade on the OTC Pink Current Information. The Company has their headquarters in Holbrook, New York.

The Company’s products include Snorenz©, a patented spray for snoring relief.Snorenz© isa throat spray that reduces or eliminates the sounds ordinarily associated with snoring. This product is free of artificial colors, flavors, or preservatives. Snorenz©’s patented ingredients, technology, and manufacturing process delivers consistent and measured droplet spray mists directly to the back of the throat. It lubricates the uvula and soft palate that vibrate with each breath.

Northstar’s products also include Stem-Intense, a unique stem cell replacement therapy supplement. In addition, their products include Health-Enrich for pets, a new supplement that promotes pet health and can help relieve many problems experienced by aging pets.

Last month,Northstar Global Business Services announced that the Company hascommenced implementation of their online sales and marketing strategy. This strategy will begin with some major names including Amazon.com among others.Amazon invited Northstar to become a supplier of Snorenz© so that the product may be sold in Amazon's own online health and beauty section.The expectation is that the relationship willincrease online sales considerably, and take place quite quickly in comparison to the other relationships announced by Northstar Global.

Today,Northstar Global announced that the Company has decided to fast-track the release of two of their most anticipated products: Goodnight’s Sleep and Snorenz Nighttime. Originally slated for release in early 2014, both of these products will be available for purchase by the end of August 2013.

Goodnight’s Sleep is an all-natural oral spray sleep aid. Snorenz Nighttime is a version of Northstar Global’s top selling all natural anti-snoring spray with a safe and effective sleep inducing formula added.

Northstar Global Business Services, Inc. (MDIN), closed Tuesday’s trading session at $0.0018, up 12.50%, on 18,410,074 volume with 68 trades. The average volume for the last 60 days is 7,226,232 and the stock's 52-week low/high is $0.0001/$0.0107.

Sitoa Global, Inc. (STOA)

Pennybuster, Penny Stocks24, Bird Gang Stocks, Stock Analyzer, and ThePUMPTracker reported on Sitoa Global, Inc. (STOA), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Sitoa Global, Inc.specializes in providing e-commerce solutions and services that enablemulti-channel B2C (Business-to-Consumer) and B2B (Business-to-Business) transactions.The Companyworks to facilitate new advances in e-commerce through building and managing leading online marketplaces that match online sellers with targeted customer groups. Sitoa Global lists on the OTCQB; the Company has their headquarters inWan Chai, Hong Kong.

Sitoa Global provides a user-friendly and complete platform, the "Focused Social Marketplace." It enables online retailers to employa social marketplace e-commerce site.  Sitoa Global's platform allows building marketplaces for online sellers with focused social customer networks to increasetheir sales channels without the risks of focus dilution, and increased capital and operating costs.  Sitoa Global shares in revenues createdby the site on top ofcharging integration and hosting fees.

Currently, the Company hosts several existing e-commerce solutions. These include4-GS, Ltd. (a B2B e-commerce platform); ZBL Cybermarketing, Ltd. (Google's largest Search Engine Marketing (SEM) and Search Engine Optimization (SEO) provider in Northern China);iMedia, Ltd. (a mobile advertising platform), and Chunjie365 (a bi-lingual e-commerce site in China).

This past March,Sitoa Global announced that the Company entered into a Letter of Intent (LOI) with IRIS Corporation Berhad (IRIS). IRIS is a foremost, diversified, technology company.IRIS is the owner of certain selected waste-to-energy assets; and other Renewable Energy and waste to energy "Pipeline Project" assets, owned by third-party owners and with whom IRIS will secure appropriate agreements to these projects, technologies, rights and obligations.

This is all regarding a proposed transaction in which Sitoa Global will purchase IRIS Renewable Energy Assets plus waste-to-energy assets owned by other third parties in exchange for common shares in Sitoa Global. Upon completion of the acquisitions, IRIS will become the majority shareholder of Sitoa as a result of the share exchange. Sitoa Global will pursue the development of the acquired renewable energy business in harmony with IRIS's business plan. 

Sitoa Global, Inc. (STOA), closed Tuesday’s trading session at $0.002, up 33.33%, on 56,101,295 volume with 165 trades. The average volume for the last 60 days is 28,015,855 and the stock's 52-week low/high is $0.0011/$0.15.

Vizstar, Inc. (VIZS)

Wallstreetlivechat, MoneyTV, PennyStocks24, HotOTC, MajorPennyStocks, Actual Gains, Bullseyestox.com, PennyStockRumors.net, PricelessPenny, Wallstreetbuzz, Penny Champions, Penny Dreamers, and Stock Twiter reported recently on Vizstar, Inc. (VIZS), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Vizstar, Inc. isan aggregator of companies and products in the organic cosmetic, wellness, and skincare markets. The Company focuses on businessesthat are U.S.D.A. Certified Organic that possess both patents and distribution.Vizstar is concentrating on worldwide distribution and branding of the Kimberly Parry name. The Company has their corporate headquarters in San Clemente, California. Vizstar lists on the OTC Pink Current Information.

Vizstar centers on purchasing companies that have high growth potential and that have been in business for 3 – 5 years. TheirKimberly Parry Organics creates luxurious spa products that utilize the power of botanicals and aromatherapy. Kimberly Parry spa products are USDA certified organic and made fresh to order at the Company’s San Clemente manufacturing facility.

Kimberly Parry Organics offers a complete spectrum of products. These include organic skin care, organic bath and body products, organic mom and baby care, as well as luxurious organic spa treatments for destination, resort, and day spas.

Recently,Vizstar announced that Kimberly Parry will showcase their product line at The International Spa Association show in Las Vegas, Nevada.Kimberly Parry will be at ISPA Conference and Expo from October 21 – 23, 2013 at the Mandalay Bay Resort and Casino in Las Vegas, Nevada.The International SPA Association has received recognitionaround the world as the professional organization and voice of the spa industry. They represent health and wellness facilities and providers in more than 70 countries.ISPA progresses the spa industry by providing vital educational and networking opportunities, promoting the value of the spa experience, and speaking as the authoritative voice to promote professionalism and growth.

Today,Vizstar announced that Kimberly Parry has retained Super Lawyer Mr. Brian A. Newman for corporate counsel.Kimberly Parry has retained the Law Office of Mr. Newman for the Company’s Corporate Counsel and Contract Review. Brian A. Newman brings more than 30 years of law experience to Kimberly Parry. Mr. Newman is recognized by Super Lawyers of 2013 for his exceptional record and dedication.

Vizstar, Inc. (VIZS), closed Tuesday’s trading session at $0.0008, down 27.27%, on 225,464,779 volume with 324 trades. The average volume for the last 60 days is 18,473,529 and the stock's 52-week low/high is $0.0003/$0.50.

Aethlon Medical, Inc. (AEMD)

PennyStocks24 and Pennybuster reported today on Aethlon Medical, Inc. (AEMD), RedChip, Investor Ideas did earlier, and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Aethlon Medical, Inc.'s mission is to create novel medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Their Aethlon ADAPT™ System (Adaptive Dialysis-Like Affinity Platform Technology) is a revenue-stage technology platform. This system provides the foundationfor a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. Aethlon Medical is based in San Diego, California.

The Aethlon ADAPT™ System is a medical device platform that joinssingle or multiple affinity drug agents with advanced plasma membrane technology. This is to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without the loss of essential blood components.

The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer. It also includes a medical device undergoing development under a five-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers (DARPA Sepsis Program).

Aethlon Medical’s Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens. These include the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and a number of bioterror and pandemic threats. In addition, the Company has their HER2osome™. It provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer.

Moreover, Aethlon has their ELLSA™ Exosome Assay. This is an enzyme-linked lectin-specific assay that has demonstrated the ability to identify and quantify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and all forms of cancer tested to date.

In June,Aethlonrevealed that the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that allows Aethlon Medical to begin human feasibility studies of the Aethlon Hemopurifier® in the U.S.  

In July,Aethlon Medicalannounced that the European Patent Office provided the Company with a Decision To Grant A Patent entitled "Method of removal of viruses from blood by lectin affinity hemodialysis".  The European Patent will be assigned Patent No. 1624784; it has been referenced in European Patent Office Bulletin No. 13/29.  The registration of the patent expands the protection of the Aethlon Hemopurifier®; it includes designations in the United Kingdom, Germany, Ireland, Italy, France, and Belgium.

Aethlon Medical, Inc. (AEMD), closed Tuesday at $0.265, up 41.71%, on 2,703,732 volume with 364 trades. The average volume for the last 60 days is 403,189 and the stock's 52-week low/high is $0.06/$0.20.

Anavex Life Sciences Corp. (AVXL)

Investors Alley, PennyStocks24, Oakshire News Bulletin, Trade of the Week, Insider Wealth Alert, Wyatt Investment Research, Dividend Opportunities, StreetAuthority Financial, and SmarTrend Newsletters reported earlier on Anavex Life Sciences Corp. (AVXL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2004, Anavex Life Sciences Corp.is a biopharmaceutical companyinvolved in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing their proprietary drug discovery SIGMACEPTOR™ platform.The Company’s portfolio consists of novel, wholly owned sigma receptor agonists and antagonists.Anavex Life Sciences’ shares trade on the OTC Markets OTCQB.

The Company’slead drug candidate for Alzheimer’s disease (AD) is ANAVEX 2-73. It has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. ANAVEX 2-73 was well tolerated in doses up to 55mg.  Conducted pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. 

In addition, Anavex hascommenced scale-up manufacturing for ANAVEX 1-41. This is the Company’s second lead compound, targeting depression and AD.At the core of the Company’sinventive approach to drug development is their proprietary SIGMACEPTOR™ Discovery Platform developed by Dr. Alexandre Vamvakides, the Company’s scientific founder.

Pertaining to Neurological diseases, theAnavex SIGMACEPTOR™-N program involves the discovery and development of original drug candidates, targeting neurological diseases such as AD, epilepsy, and depression. ConcerningOncology, the Anavex SIGMACEPTOR™-C program involves the discovery and development of original drug candidates targeting cancer. Furthermore,several series of sigma ligands now at different stages of development, target stroke, diabetes, multiple sclerosis and Parkinson’s disease.

This past May,Anavex Life Sciences announced that they were invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation (ADDF) for a Phase 2a trial of ANAVEX 2-73.  The ADDF, since 1998, has granted greater than $51 million in venture philanthropy funding to projects with potential viability in the market.

Recently,Anavex Life Sciences announced the closing of $2.6-million in a private placement financing and conversion of liabilities and an agreement with institutional investor Lincoln Park Capital Fund, LLC for a funding commitment of up to $10-million with an initial investment of $100,000. 

The Company also announced the appointment of experienced healthcare executive Dr. Christopher U. Missling as Chief Executive Officer of Anavex Life Sciences.

Anavex Life Sciences Corp. (AVXL), closed today at $0.6001, up 17.67%, on 547,515 volume with 232 trades. The average volume for the last 60 days is 92,902 and the stock's 52-week low/high is $0.41/$1.36.

Iona Energy, Inc. (IONAF)

Today we are reporting on Iona Energy, Inc. (IONAF), here at the QualityStocks Daily Newsletter.

Iona Energy, Inc.is a Canadian oil and gas company based in Scotland. The Company focuses on value creation from the mature parts of the oil and gas value chain.Through their operating subsidiaries, Iona US and Iona UK, the Company is active in the U.S. (Alaska) and the UK Continental Shelf. The Company’s principal focus is the UK North Sea. Iona Energy holds five core plays in the UK North Sea - four crude oil development projects (Huntington, Orlando, Kells and West Wick) and one natural gas development project (Trent & Tyne).

The Company’s management team has considerable North Sea experience. Iona Energy lists on the OTC Markets’ OTC Pink Current Information. Iona has an office in Aberdeen, Scotland, and an office in Calgary, Alberta.

Ionaengages in theappraisal and development of existing proven undeveloped oil and gas accumulations, the redevelopment of previously producing fields and the exploitation of already existing producing fields via renewed late-life field development and increased oil recovery initiatives. Furthermore, Iona Energy sometimes engages in low risk infrastructure led exploration efforts to maximize value from existing infrastructure.

The centering of the Company’s license policy is on targeted acquisitions and licensing round applications supporting this strategy within well-known and established hydrocarbon basins. As of December 31, 2012, Iona Energy had estimated 2P reserves of 36.0 MMboe(Million Barrels of Oil Equivalent), all of which are related to the aforementioned five assets.

Regarding operations, the Company’sHuntington play is a medium-sized oil field located in block 22/14b in the Central North Sea approximately 230 kilometers east of Aberdeen. Orlando is a small oil field located in UKCS Block 3/3b on the west flank of the Viking Graben in the Northern North Sea.Kells is situated in Block 3/8d in the Northern North Sea approximately 130 kilometers east of Shetland in the North Viking Graben.

West Wick is a moderately heavy oil reservoir situated in the outer Moray Firth in Block 13/21 of the Central North Sea.Trent & Tyne are two gas fields in the UK Southern North Sea. They are approximately 130 kilometers and 170 kilometers east of Scarborough, on the English east coast, respectively.

In addition, Iona has theirRonan & Oran operation.The undeveloped Ronan and Oran discoveries (formerlynamed Aidan and Nadia) are within the Brent Group sandstones. They are approximately 20 kilometers to the southwest of the Ninian Central Platform (NCP) and 15 kilometers west of Iona Energy's Kells field. 

Iona Energy, Inc. (IONAF), closed Tuesday’s session at $0.51, even for the day, on 1,121,350 volume with 25 trades. The average volume for the last 60 days is 182,991 and the stock's 52-week low/high is $0.359/$0.718.

graphic

The QualityStocks
Company Corner

graphic
graphic

OxySure Systems, Inc. (OXYS)

The QualityStocks Daily Newsletter would like to spotlight OxySure® Systems, Inc. (OXYS). Today, OxySure Systems, Inc. closed trading at $0.84, up 15.23%, on 41,523 volume with 31 trades. The stock’s average daily volume over the past 60 days is 6,363, and its 52-week low/high is $0.35/$2.75.

OxySure Systems, Inc. delivered a one-two punch today, with the dual announcements that the company has engaged the investor relations and social media relations services of DreamTeamGroup (DTG), as well as resolved the strategic market potential of their revolutionary OxySure Model 615 technology, which represents an emergency oxygen solution like the typical Automated External Defibrillators in use around the world. The OxySure Model 615 combines two inert powders to produce medically pure oxygen via a unique device that almost anyone can operate and the company is extremely pumped to be leveraging DTG's vast network of investor-oriented sites and full team of dedicated professionals to help broaden the company's growing influence.

OxySure Systems, Inc. (OXYS) is a medical technology company focused on developing, manufacturing, and distributing specialty respiratory and medical solutions. The company has developed a unique platform technology that instantly creates medically pure oxygen from two dry, inert powders, allowing oxygen to be delivered on demand. This cutting-edge technology has already been granted FDA-approved for commercial sale.

The company is targeting multiple enormous end markets with no direct competition. OxySure initially plans to focus on the 102,265 educational campuses, 350,735 manufacturing facilities, 350,000 churches, 12 million recreational vehicles (RVs), 8 million boats and yachts, 950,000 restaurants, and hundreds of thousands of other commercial and municipality facilities in the U.S. Outside the US, OxySure has also already signed significant distribution agreements, including Australia, New Zeeland, the United Kingdom, the Netherlands, Luxembourg, Belgium, Brazil, and South Africa. OxySure’s potential market is at least as large as AEDs and potentially as large as fire extinguishers, which together total at least 500+ million units worldwide.

OxySure’s flagship product, OxySure Model 615, introduces the first new oxygen technology in 50 years. There are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, and no required training, and the technology is both safe and easy-to-use for the layperson. It can be placed virtually anywhere to help save lives by bridging the gap between a medical emergency and the arrival of first responders on the scene.

The company aims to capitalize on market opportunities primarily through partnerships with distributors and OEM customers. Protected by numerous issued patents and patents pending, the company’s products are available over-the-counter without the need for a prescription and has already saved thousands of lives around the globe during various types of medical emergencies. Disclaimer

OxySure Systems, Inc. Company Blog

OxySure Systems, Inc. News:

OxySure's Strategy To Realize Its Market Potential

OxySure Systems, Inc. Announces Engagement of DTG's IR and SMR Services

Taglich Brothers Initiates Coverage on OxySure Systems with Speculative Buy Rating

Epazz Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz Inc. (EPAZ). Today, Epazz Inc. closed trading at $0.0017, up 13.33%, on 56,039,908 volume with 284 trades. The stock’s average daily volume over the past 60 days is 11,885,439 and its 52-week low/high is $0.0006/$0.045.

Epazz Inc. announced today that the company is moving quickly forward with the Project Human Mobile Power spinoff, a project to develop a mobile power device that allows iPhone and other smartphone users to power up their phone on the go without needing an outlet or a second battery. Epazz is currently working with a Patent attorney to file for patent pending status on this technology and the company is also pursuing other acquisitions that are already cash flow positive, with several current ongoing negotiations aimed at picking up other key B2B software companies as part this long-term strategic growth plan.

Epazz Inc. (EPAZ) is a leading cloud-based software company focused on providing customized cloud applications to Fortune 500 enterprises, government agencies, and higher education institutions. Targeting a strong growth industry, the company is rapidly expanding via strategic acquisitions, a full suite of in-house products and services, and diversified streams of income.

The fully reporting company is demonstrating substantial performance in a competitive industry, completing six acquisitions while maintaining organic subsidiary growth. In the last three years, Epazz revenues have increased by more than 300%. The company will produce its first spinoff with “Project Flex” and issue a stock dividend to shareholders of record on the record date.

As an enterprise-wide software company, Epazz is adeptly serving the increasing information technology demand of the 21st century. According to IDC, the premiere global market intelligence firm, the IT cloud services industry is expected to grow from $40 billion to $100 billion in just four years. Management anticipates the company’s growth to accelerate as the market for its technology solutions continues to expand.

Epazz BoxesOS™ v3.0 is the complete business web-based software package for small to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. The turnkey enterprise system, which includes content, integration, customization, and marketing services, provides many of the web-based applications organizations would have to otherwise buy separately. Disclaimer

Epazz Inc. Blog

Epazz Inc. News:

Epazz Advances Project Human Mobile Power Spinoff

Epazz Revenues up Over 1,000 Percent Since Going Public

Epazz Reaches Over 100 Million Shares on Short Sales Report for July 2013

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.1605, up 6.29%, on 693,157 volume with 166 trades. The stock’s average daily volume over the past 60 days is 278,595, and its 52-week low/high is $0.135/$0.41.

International Stem Cell Corp. announced today that it has issued an Executive Informational Overview on International Stem Cell Corporation, the full 72-page report of which is available at www.crystalra.com. In focus are key biotech innovations and work by the company done in developing and commercializing therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and eye, as well as on other biomedical products, in addition to the ongoing creation of a stem cell bank, UniStemCell™.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

Crystal Research Associates Issues Executive Informational Overview on International Stem Cell Corporation

International Stem Cell Corporation Announces Pricing of Public Offering

International Stem Cell Corporation to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting

Dragon Capital Group Corp. (DRGV)

The QualityStocks Daily Newsletter would like to spotlight Dragon Capital Group Corp. (DRGV). Today, Dragon Capital Group Corp. closed trading at $0.0025, even with yesterday's close, on 23,566,290 volume with 118 trades. The stock’s average daily volume over the past 60 days is 2,172,433 and its 52-week low/high is $0.0009/$0.01.

Dragon Capital Group Corp. announced today that Shanghai City North Gas Company, Ltd. has selected its Shanghai Yazheng Information Technology Company subsidiary to carry out a gas valve grouping system project based on Yazheng's ARC/INFO Gas Information System. The project is designed to improve the overall efficiency of a portion of Shanghai City North's gas pipeline network. Its main focus is on setting up and optimizing the grouping of the valve network in order to reduce the number of customers affected by any pipe network failure and to quickly determine the need for specific repair and maintenance so that expenses can be significantly reduced.

Dragon Capital Group Corp. (DRGV) operates through its six subsidiaries in the People's Republic of China with a specific focus on the technology market. Serving as a conduit between Chinese high-growth companies and Western investors, the company provides support in the critical functions of general business consulting, formation of joint ventures, access to capital, merger & acquisition, business valuation, and revenue growth strategies.

The development of wireless applications and business solutions is a large area of focus. Two companies Dragon has acquired are among the leading providers of mobile applications and business software in China. Shanghai Zhaoli, one of these two companies, recently received a Ten Year Outstanding Contribution Award from HP to recognize the distinguished contribution made as HP's foreign authorized distributor in Greater China Region.

Through its subsidiaries, Dragon represents a wide array of name brand manufacturers, including Hewlett Packard, Epson, Canon, Ricoh, Brother, Star, and Samsung. Dragon’s seasoned professionals have experience with both the laws and business practices of China. This experience serves as a competitive advantage for Dragon’s portfolio companies.

Dragon aims to emerge as a significant force in the high-tech sector of China. Employing expertise of Chinese and U.S. business practices, Dragon is establishing a successful track record nurturing Chinese companies. The company’s unique combination of professionals represents a powerful resource critical to maintaining and accelerating its growth. Disclaimer

Dragon Capital Group Corp. Blog

Dragon Capital Group Corp. News:

Shanghai City North Gas Company, Ltd. to Use Dragon Capital Group's Gas Information System for Gas Valve Grouping Project

Dragon Capital Group, Inc. Reports Financial Results for the Second Quarter and First Six Months of 2013 Ended June 30, 2013

Dragon Capital Group Subsidiary Receives 2013 Government Sponsorship from Shanghai Innovation Fund for Technology-Based Firms

OxySure Systems, Inc. (OXYS) Engages DTG to Enhance Corporate Communications

Today before the opening bell, OxySure announced that it has enlisted the investor relations (IR) and social media relations (SMR) services of DreamTeamGroup (DTG). Leveraging a network of investor-oriented sites and full team of dedicated professionals, DTG broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.

“Leveraging numerous patents and patents pending, OxySure has demonstrated its ability and dedication to consistently create new products and opportunities, and build company value,” stated Sherri S. Franklin, Director of Marketing at DTG. “OxySure has positioned itself to capitalize on a wealth of market opportunities by fostering several partnerships with leading companies in the emergency medical, EMS, first aid, safety and MRO markets.”

Julian T. Ross, CEO of OxySure, commented, “We have pioneered our patent protected technology and are the first to market these products, a significant step in establishing our foothold in the industry. By engaging a reputable full-service investor relations firm we are prepared to further extend our global market reach and enhance social media communications. DTG is providing a much needed service in the small-cap markets.”

DreamTeamGroup (DTG) combines very different, but complementary marketing avenues into one dynamic approach. This interlocking marketing convergence tackles many obstacles in the marketing process by engaging many different types of individuals with compelling content. By providing unique offerings, DTG has become a valuable advertising outlet garnering a top placement in traffic and unique hits.

For more information on OxySure Systems, visit www.OxySure.com

Epazz, Inc. (EPAZ) One Step Closer to Executing Second Spin-off Project

Epazz, a provider of cloud-based business software solutions, is rapidly advancing its second spin-off project, Human Mobile Power, and is currently working with a patent attorney to file for a patent pending status on the device.

Project Human Power is a project to develop a mobile power device for iPhone and other smartphones that allows users to charge their phone without the need for an outlet or second battery. Because the product is not directly in line with Epazz’s core business, the company believes the project creates opportunity for a spin-off to spur growth and shareholder value.

Epazz’s strategy is to pursue acquisitions that are already cash flow positive and spin-off each acquisition into its own publicly traded company with a dividend being paid to shareholders. Over the last two years, the company has completed two acquisitions and is currently in process of completing a third.

“We have been working hard on both the business end and the public company end to bring Project Flex, our first spin off project, to fruition,” Shaun Passley, CEO of Epazz, stated in the press release. “Our company is at a point now that we can begin announcing things like dates and percentages as well as other significant information. Project Flex and Project Human Power are going to make a big difference to our bottom line and for our shareholders.”

As part of its long-term growth plan focused on the acquisition of profitable B2B software companies, Epazz is currently in negotiations to acquire several other B2B software companies.

For more information, visit www.epazz.com

International Stem Cell Corp. (ISCO) Receives Coverage from Crystal Research Associates

Crystal Research Associates, an independent research firm that has provided institutional-quality research on small-cap and mid-cap companies for the past decade, has issued an Executive Informational Overview® on International Stem Cell Corporation. The complete 72-page report is available on Crystal Research Associates’ website at www.crystalra.com.

International Stem Cell Corporation is a biotechnology company focused on therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and eye, as well as on the development and commercialization of biomedical products. According to the company, hpSC is the only histocompatible stem cell platform capable of generating stem cell lines that can immune-match millions of people. ISCO has focused its therapeutic efforts in three markets where cell therapy has been clinically proven, but where there is a shortage of safe cells or tissue: (1) Parkinson’s disease (PD); (2) inherited metabolic liver disease; and (3) corneal blindness. Together these markets have an estimated revenue potential of over $5 billion.

ISCO is also developing a stem cell bank, UniStemCell™, which already contains enough histocompatible stem cell lines to immune-match over 75 million people. In addition, the company produces and markets specialized cells and growth media for therapeutic research through its subsidiary Lifeline Cell Technology, and stem cell-based skin care products through its subsidiary Lifeline Skin Care. Revenue generated from ISCO’s subsidiaries — which totaled $4.6 million in 2012 — supports the development of the company’s therapeutic programs. ISCO believes that its proprietary technology platform and business model result in three key competitive advantages: immune-matching stem cells, proven cell therapy targets, and substantial revenue from commercial operations.

Crystal Research Associates is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street as well as for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

For additional information, visit www.InternationalStemCell.com

Dragon Capital Group Corp. (DRGV) Selected by Shanghai City North Gas Company for Gas Valve Grouping Project

Dragon Capital Group, a leading holding company of emerging high-tech companies in China, today announced that Shanghai City North Gas Company, Ltd. has chosen its Shanghai Yazheng Information Technology Company (“Yazheng”) subsidiary to carry out a gas valve grouping system project based on Yazheng’s ARC/INFO Gas Information System.

The project is designed to improve the overall efficiency of a portion of Shanghai City North’s gas pipeline network. Its main focus is on setting up and optimizing the grouping of the valve network in order to reduce the number of customers affected by any pipe network failure and to quickly determine the need for specific repair and maintenance so that expenses can be significantly reduced.

Yazheng’s management believes that after years of development it has made a significant breakthrough in gas pipeline management with its Gas Information System. The modeling of optimum valve configuration coupled with the GIS monitoring can significantly reduce outages and proactively target maintenance to reduce incidences of breakdowns in the network. Yazheng is committed to the rollout of GIS throughout China and eventually to other countries as it looks to secure a leading position in this area.

Mr. Lawrence Wang, Chairman and CEO of Dragon Capital Group, stated, “We are very pleased to have been selected by Shanghai City North to provide Yazheng’s GIS to optimize their gas pipeline network. While this initial project is narrow in its scope, it represents a significant first step in the rollout of this important software. We believe projects of this nature will validate the utility of our system and lead to larger and more expansive projects throughout China as well as in other countries. Maximizing the efficiencies of these networks is critical as utility companies search for ways to reduce costs to defray the costs of rising energy prices. We look forward to building GIS into a highly profitable source of revenue for Dragon Capital in the coming years for the benefit of our stockholders.”

For more information, visit www.dragoncapital.us

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

FOX Penny Stocks
(IALS)

2.

OtcWizard
(CGFI)

3.

Wallstreetlivechat
(MLTC)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251